Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

By Disis M.L.   Knutson K.L.   Schiffman K.   Rinn K.   McNeel D.G.  

Breast Cancer Research and Treatment, Vol. 62, Iss. 3, 2000-08 ,pp. : 245-252

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic and Predictive Impact of the HER-2/ neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer

By Müller Volkmar   Witzel Isabell   Lück Hans   Köhler Günter   Minckwitz Gunther   Möbus Volker   Sattler Daniel   Wilczak Waldemar   Löning Thomas   Jänicke Fritz   Pantel Klaus   Thomssen Christoph  

Breast Cancer Research and Treatment, Vol. 86, Iss. 1, 2004-07 ,pp. : 9-18

Springer Publishing Company

Access to resources Recommend Favorite

Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/ neu in Patients with Breast Cancer

By Taucher Susanne  

Breast Cancer Research and Treatment, Vol. 82, Iss. 3, 2003-01 ,pp. : 207-213

Springer Publishing Company

Access to resources Recommend Favorite

HER-2/neu Assessment in Primary Chemotherapy Treated Breast Carcinoma: No Evidence of Gene Profile Changing

By Dagrada G.P.  

Breast Cancer Research and Treatment, Vol. 80, Iss. 2, 2003-07 ,pp. : 207-214

Springer Publishing Company

Access to resources Recommend Favorite

Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer

By Modi Shanu   DiGiovanna Michael   Lu Zhao   Moskowitz Chaya   Panageas Katherine   Van Poznak Catherine   Hudis Clifford   Norton Larry   Tan Lee   Stern David   Carter Darryl   Seidman Andrew  

Cancer Investigation, Vol. 23, Iss. 6, 2005-09 ,pp. : 483-487

Informa Healthcare

Access to resources Recommend Favorite